切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (03) : 150 -158. doi: 10.3877/cma.j.issn.1674-0807.2019.03.004

所属专题： 文献；

论著

乳腺癌保留乳房手术中放射治疗有效性和安全性的Meta分析
薛玉1, 徐晓帆2, 顾军2,†()   
  1. 1. 210009　南京，东南大学医学院临床医学系
    2. 210002　南京，解放军东部战区总医院普通外科研究所
  • 收稿日期:2018-12-28 出版日期:2019-06-01
  • 通信作者: 顾军
  • 基金资助:
    南京军区南京总医院课题资助项目(2015021); 江苏省社会发展基金资助项目(BE2017726)

Efficacy and safety of intraoperative radiotherapy in breast conservative surgery for breast cancer patients: a meta-analysis

Yu Xue1, Xiaofan Xu2, Jun Gu2,†()   

  1. 1. Department of Clinic Medicine, School of Medicine, Southeast University, Nanjing 210009, China
    2. Research Institute of General Surgery, General Hospital of Eastern Military Command of PLA, Nanjing 210002, China
  • Received:2018-12-28 Published:2019-06-01
  • Corresponding author: Jun Gu
  • About author:
    Corresponding author: Gu Jun, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

薛玉, 徐晓帆, 顾军. 乳腺癌保留乳房手术中放射治疗有效性和安全性的Meta分析[J/OL]. 中华乳腺病杂志(电子版), 2019, 13(03): 150-158.

Yu Xue, Xiaofan Xu, Jun Gu. Efficacy and safety of intraoperative radiotherapy in breast conservative surgery for breast cancer patients: a meta-analysis[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(03): 150-158.

目的

评价乳腺癌保留乳房手术中放射治疗的有效性和安全性。

方法

用计算机检索中国知网、维普、万方、PubMed、Cochrane、Web of Science和Embase数据库，检索时限为建库至2018年12月20日，收集有关乳腺癌保留乳房手术中放射治疗有效性和安全性的临床试验研究。由2名研究者独立按照纳入及排除标准进行文献筛选、资料提取、方法学质量评价后，采用RevMan 5.3软件对纳入研究进行Meta分析。

结果

共纳入12项研究，包括8项随机对照研究(RCT)和4项非RCT，共6 277例患者。与术后放射治疗者比较，术中放射治疗患者的局部复发率更高(RR＝2.78，95%CI: 1.25～6.19，P＝0.01)，切口愈合时间更长[均数差(MD)＝5.92，95%CI: 5.46～6.37，P<0.01]，但在远处转移率和OS率方面与术后放射治疗者比较，差异均无统计学意义(RR＝0.92，95%CI: 0.62～1.37，P＝0.68；RR＝1.01，95%CI: 1.00～1.01，P＝0.26)。术中放射治疗患者的美容优良率高于术后放射治疗(RR＝1.17，95%CI: 1.05～1.31，P<0.01)。术中放射治疗患者的脂肪液化率和渗出率与术后放射治疗患者比较，差异均无统计学意义(RR＝2.18，95%CI: 0.71～6.72，P＝0.18；RR＝1.55，95%CI: 0.36～6.68，P＝0.56)。

结论

术中放射治疗在远处转移率、总生存率及不良反应方面与术后放射治疗相似，且有更好的美容效果，但其局部复发率可能更高，应选择复发风险较低的患者。

关键词: 乳腺肿瘤, Meta分析, 放射疗法, 保留乳房手术
Objective

To evaluate the clinical efficacy and safety of intraoperative radiotherapy in breast conservative surgery for breast cancer patients.

Methods

The databases including CNKI, VIP, Wanfang, PubMed, Cochrane, Web of Science, Embase were retrieved to identify clinical trials which investigated the efficacy and safety of intraoperative radiotherapy in breast conservative surgery from the date of establishment to December 20, 2018. Two researchers independently performed literature screening, data extraction, and methodological quality evaluation according to the inclusion and exclusion criteria. An meta-analysis of the included studies was performed using RevMan 5.3 software.

Results

Totally 12 clinical trials (6 277 subjects) including 8 randomized controlled trials (RCT) and 4 non-RCT were enrolled. Meta-analysis showed that the local recurrence rate in patients with intraoperative radiotherapy was significantly higher than that in patients with postoperative radiotherapy (RR=2.78, 95%CI: 1.25-6.19, P=0.01), and the wound healing time was significantly longer [mean difference (MD)=5.92, 95%CI: 5.46-6.37, P<0.01]. There was no significant difference in distant metastasis rate and overall survival between intraoperative radiotherapy group and postoperative radiotherapy group (RR=0.92, 95%CI: 0.62-1.37, P=0.68; RR=1.01, 95%CI: 1.00-1.01, P=0.26). The patients undergoing intraoperative radiotherapy had significantly better cosmetic effect compared with the patients with postoperative radiotherapy (RR=1.17, 95%CI: 1.05-1.31, P<0.01). The fat liquefaction rate and exudation rate presented no significant difference between intraoperative radiotherapy group and postoperative radiotherapy group(RR=2.18, 95%CI: 0.71-6.72, P=0.18; RR=1.55, 95%CI: 0.36-6.68, P=0.56).

Conclusion

Intraoperative radiotherapy is not inferior to postoperative radiotherapy in distant metastasis rate, overall survival and adverse reaction, but with better cosmetic effect and a higher local recurrence rate, so the patients with low risk of recurrence are recommended.

Key words: Breast neoplasms, Meta-analysis, Radiotherapy, Breast conservative surgery
图1 文献筛选流程及结果
表1 纳入研究的基本情况
纳入研究 年份 研究设计 例数(T/C) 年龄(岁) 肿瘤直径(cm) 随访时间(月) 干预措施 结局指标 质量评分
Vaidya[3] 2016 RCT 1 721/1 730 ≥45 ≤3.5 29 T:术中20 Gy 50 kV X线；C:体外放射治疗 ①②③⑦ 5b
Veronesi[4] 2013 RCT 651/654 48～75 ≤2.5 70 T:术中21 Gy；C:全乳放射治疗 ①②③⑦ 5b
孙春雷[8] 2010 非RCT 36/41 35～69 ≤2.5 30 T:术中21 Gy 9 MeV电子线3～5 min；C:全乳放射治疗50～60 Gy，5～6周(全乳50 Gy，瘤床加量至60 Gy) ①②④⑤ 18a
Zhou[9] 2012 非RCT 72/71 ≥40 ≤2.5 32 T:术中21 Gy 9/12 MeV电子线3～5 min；C:术后传统放射治疗 ①②③④⑥ 20a
Cracco[10] 2015 非RCT 81/105 38～81 ≤3.0 17 T:术中21 Gy；C:体外放射治疗 ④⑥⑦ 21a
Sorrentino[11] 2018 非RCT 223/220 ≥50 ≤3.0 ≥12 T:术中21 Gy 2～4 min；C:体外放射治疗 ①②③⑥ 22a
Sperk[12] 2012 RCT 54/55 T:中位64.4;C:中位69.0 ≤3.5 40 T:术中20 Gy；C:全乳放射治疗46～50 Gy ①②③ 4b
肖海燕[13] 2013 RCT 70/70 33～68 未提及 8～24 T:术中21 Gy 9/12 MeV电子线3～5 min；C:全乳放射治疗 ①②③④⑤ 2b
彭宗玉[14] 2013 RCT 60/60 29～68 ≤2.5 8～24 T:术中21 Gy 9/12 MeV电子线3～5 min；C:全乳放射治疗 ①②③④⑤⑥ 3b
董世亮[15] 2016 RCT 44/44 30～68 ≤2.5 12 T:术中21 Gy 9/12 MeV电子线3～5 min；C:全乳放射治疗 ④⑥⑦ 2b
刘军[16] 2017 RCT 54/55 30～68 ≤3.0 12 T:术中21 Gy 9 MeV电子线5 min；C: 21 Gy全乳放射治疗 ②④⑥⑦ 2b
宋艾红[17] 2018 RCT 53/53 45～71 ≤3.0 60 T：术中9 Gy 9/12 MeV电子线3～5 min；C:全乳放射治疗 ②③④⑤⑥ 5b
图2 术中放射治疗组与术后放射治疗组乳腺癌患者局部复发率的森林图及异质性检验结果
图3 术中放射治疗组与术后放射治疗组乳腺癌患者远处转移率的森林图及异质性检验结果
图4 术中放射治疗组与术后放射治疗组乳腺癌患者总生存率的森林图及异质性检验结果
图5 术中放射治疗组与术后放射治疗组乳腺癌患者美容优良率的森林图及异质性检验结果
图6 术中放射治疗组与术后放射治疗组乳腺癌患者切口愈合时间的森林图及异质性检验结果
图7 术中放射治疗组与术后放射治疗组乳腺癌患者脂肪液化率的森林图及异质性检验结果
图8 术中放射治疗组与术后放射治疗组乳腺癌患者渗出率的森林图及异质性检验结果
图9 术中放射治疗组与术后放射治疗组乳腺癌患者远处转移率比较的论文发表偏倚漏斗图
[1]
Reintgen C, Reintgen D, Solin LJ. Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field [J]. Clin Breast Cancer, 2010, 10(3): 180-187.
[2]
Esposito E, Anninga B, Harris S. Intraoperative radiotherapy in early breast cancer[J]. Br J Surg, 2015, 102(6): 599-610.
[3]
Vaidya JS, Wenz F, Bulsara M, et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) [J]. Health Technol Assess, 2016, 20(73): 1-188.
[4]
Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial[J]. Lancet Oncol, 2013, 14(13): 1269-1277.
[5]
Zhang L, Zhou Z, Mei X, et al. Intraoperative radiotherapy versus whole-breast external beam radiotherapy in early-stage breast cancer: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2015, 94(27): e1143.
[6]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary？[J]. Control Clin Trials, 1996，17:1-12.
[7]
Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument [J]. ANZ J Surg，2003，73(9):712-716.
[8]
孙春雷，周士福，时伟锋，等．保乳手术术中电子线照射的近期效果[J]. 江苏医药，2010，36(18):2173-2175.
[9]
Zhou SF, Shi WF, Meng D, et al. Interoperative radiotherapy of seventy-two cases of early breast cancer patients during breast-conserving surgery[J]. Asian Pac J Cancer Prev, 2012, 13(4): 1131-1135.
[10]
Cracco S, Semprini G, Cattin F, et al. Impact of intraoperative radiotherapy on cosmetic outcome and complications after oncoplastic breast surgery [J]. Breast J, 2015, 21(3): 285-290.
[11]
Sorrentino L, Fissi S, Meaglia I, et al. One-step intraoperative radiotherapy optimizes conservative treatment of breast cancer with advantages in quality of life and work resumption[J]. Breast, 2018, 39: 123-130.
[12]
Sperk E, Welzel G, Keller A, et al. Late radiation toxicity after intraoperative radiotherapy (IORT) for breast cancer: results from the randomized phase Ⅲ trial TARGIT A[J]．Breast Cancer Res Treat, 2012, 135(1): 253-260.
[13]
肖海燕．具备保留乳房条件的早期乳腺癌治疗方式选择[J]. 中国医药导刊，2013，15(10):1649-1650.
[14]
彭宗玉，张佩娟，杜国威．早期乳腺癌保乳手术联合术中放疗的临床疗效分析[J]. 中国肿瘤临床与康复，2013，20(4):380-382.
[15]
董世亮，石永刚，牛利娜，等．早期乳腺癌保乳术联合术中放疗的疗效与美容效果分析[J]．中国医疗美容，2016，6(5):29-31.
[16]
刘军，葛斌，高睿心，等．术中放疗辅助下早期乳腺癌保乳根治术的临床分析[J]. 中外医疗，2017，36(4):16-19.
[17]
宋艾红，李学刚，陈灯杰，等．保乳根治术联合术中放疗治疗乳腺癌的应用研究[J]．癌症进展，2018，16(11):1375-1378.
[18]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[19]
孙可欣，郑荣寿，顾秀瑛，等. 2000－2014年中国肿瘤登记地区女性乳腺癌发病趋势及年龄变化情况分析[J]．中华预防医学杂志，2018，52(6):567-572.
[20]
Deshmukh AA, Shirvani SM, Lal L, et al. Cost-effectiveness analysis comparing conventional, hypofractionated, and intraoperative radiotherapy for early-stage breast cancer[J]. J Natl Cancer Inst, 2017, 109(11): djx068.
[21]
Alvarado MD, Mohan AJ, Esserman LJ, et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer [J]. Ann Surg Oncol, 2013, 20(9): 2873-2880.
[22]
Rampinelli C, Bellomi M, Ivaldi GB, et al. Assessment of pulmonary fibrosis after radiotherapy (RT) in breast conserving surgery: comparison between conventional external beam RT (EBRT) and intraoperative RT with electrons (ELIOT)[J]. Technol Cancer Res Treat, 2011, 10(4): 323-329.
[23]
Kulcenty KI, Piotrowski I, Zaleska K, et al. Wound fluids collected from patients after IORT treatment activates extrinsic apoptotic pathway in MCF7 breast cancer cell line[J]. Ginekol Pol, 2018, 89(4): 175-182.
[24]
Corica T, Nowak AK, Saunders CM, et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial[J]. Int J Radiat Oncol Biol Phys, 2016, 96(1): 55-64.
[25]
Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J]. J Clin Oncol, 2013，31(2):203-209.
[26]
Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) [J]. Int J Radiat Oncol Biol Phys, 2009, 74(4): 987-1001.
[27]
Leonardi MC, Maisonneuve P, Mastropasqua MG, et al. Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection [J]. Radiother Oncol, 2013, 106(1): 21-27.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[15] 王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号